OptimizeRx vs Paysign
OPRX and PAYS side by side, both in miscellaneous business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How OPRX and PAYS compare
Paysign is the larger company, worth 3.9 times as much as OptimizeRx ($538M against $138M).
On earnings, OptimizeRx is cheaper: it trades at 28.2× trailing earnings, against 28.8× for Paysign.
Paysign grew revenue faster over the last twelve months (46.7% versus −14.0% for OptimizeRx).
Paysign keeps more of each dollar of sales as profit, with a net margin of 18.5% compared with 5.3% at OptimizeRx.
Paysign scores higher on the StockData Score (15 against 11 for OptimizeRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | OPRX | PAYS |
|---|---|---|
| Size and price | ||
| Market cap | $138M | $538M |
| Share price | $7.34 | $9.52 |
| Change, 1 year | −54.6% | 74.0% |
| Change, 5 years | −89.8% | 387% |
| Beta (5Y) | 1.94 | 1.34 |
| Employees | 104 | 80 |
| StockData Score | ||
| Total score | 11 | 15 (better) |
| Valuation score | 3 | 3 |
| Growth score | 2 | 5 (better) |
| Performance score | 2 | 4 (better) |
| Health score | 4 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 28.2× (better) | 28.8× |
| P/S | 1.5× (better) | 4.9× |
| P/B | 1.0× (better) | 8.1× |
| EV/EBITDA | 8.2× (better) | 15.7× |
| P/FCF | 7.0× | 4.1× (better) |
| PEG | – | 0.33 |
| FCF yield | 14.4% | 24.2% (better) |
| Fair value | $10.52 | $11.37 |
| Margin of safety | 30.2% (better) | 16.3% |
| Growth | ||
| Revenue growth (TTM) | −14.0% | 46.7% (better) |
| Revenue growth, 5Y average | 20.4% | 27.7% (better) |
| Net income growth (TTM) | 14656% (better) | 168% |
| EPS growth (TTM) | – | 154% |
| Profitability | ||
| Gross margin | 75.3% (better) | 63.0% |
| Operating margin | 12.2% | 20.8% (better) |
| Net margin | 5.3% | 18.5% (better) |
| FCF margin | 21.1% | 118% (better) |
| Return on equity | 3.9% | 36.2% (better) |
| Return on invested capital | 5.5% | 42.7% (better) |
| Financial health | ||
| Debt / equity | 0.10 | 0.08 (better) |
| Net debt / EBITDA | −0.61 | −0.90 |
| Interest coverage | 3.1× | – |
| Current ratio | 5.06 (better) | 1.15 |
| Altman Z-score | 3.39 (better) | 1.96 |
| Piotroski F-score | 8 (better) | 7 |
| Dividends and buybacks | ||
| Buyback yield | – | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 59.6% | 53.6% |
| Held by insiders | 19.4% | 53.5% |
| Insider net buying, 12 months | −$18.8K (better) | −$8.4M |
| Short interest, % of float | 7.8% | 9.3% |
Go deeper
- OPRX stock overview
- OPRX income statement
- OPRX valuation and score
- PAYS stock overview
- PAYS income statement
- PAYS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.